IL143706A0 - Polyol/oil suspensions for the sustained release of proteins - Google Patents

Polyol/oil suspensions for the sustained release of proteins

Info

Publication number
IL143706A0
IL143706A0 IL14370699A IL14370699A IL143706A0 IL 143706 A0 IL143706 A0 IL 143706A0 IL 14370699 A IL14370699 A IL 14370699A IL 14370699 A IL14370699 A IL 14370699A IL 143706 A0 IL143706 A0 IL 143706A0
Authority
IL
Israel
Prior art keywords
oil suspensions
polyol
sustained release
proteins
active agent
Prior art date
Application number
IL14370699A
Other languages
English (en)
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/221,181 external-priority patent/US6245740B1/en
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of IL143706A0 publication Critical patent/IL143706A0/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Fats And Perfumes (AREA)
IL14370699A 1998-12-23 1999-12-20 Polyol/oil suspensions for the sustained release of proteins IL143706A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/221,181 US6245740B1 (en) 1998-12-23 1998-12-23 Polyol:oil suspensions for the sustained release of proteins
US44820599A 1999-11-23 1999-11-23
PCT/US1999/030527 WO2000038652A1 (en) 1998-12-23 1999-12-20 Polyol/oil suspensions for the sustained release of proteins

Publications (1)

Publication Number Publication Date
IL143706A0 true IL143706A0 (en) 2002-04-21

Family

ID=26915566

Family Applications (2)

Application Number Title Priority Date Filing Date
IL14370699A IL143706A0 (en) 1998-12-23 1999-12-20 Polyol/oil suspensions for the sustained release of proteins
IL143706A IL143706A (en) 1998-12-23 2001-06-12 A pharmaceutical preparation containing a biocompatible suspension of protein in poly-ol / oil

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL143706A IL143706A (en) 1998-12-23 2001-06-12 A pharmaceutical preparation containing a biocompatible suspension of protein in poly-ol / oil

Country Status (16)

Country Link
EP (1) EP1140018B1 (xx)
JP (1) JP2002533378A (xx)
KR (1) KR100491815B1 (xx)
CN (1) CN1158068C (xx)
AT (1) ATE251448T1 (xx)
AU (1) AU769610B2 (xx)
CA (1) CA2355618C (xx)
DE (1) DE69911993T2 (xx)
DK (1) DK1140018T3 (xx)
ES (1) ES2204187T3 (xx)
HU (1) HUP0104756A3 (xx)
IL (2) IL143706A0 (xx)
PT (1) PT1140018E (xx)
SI (1) SI1140018T1 (xx)
TW (1) TWI221777B (xx)
WO (1) WO2000038652A1 (xx)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7022674B2 (en) 1999-12-16 2006-04-04 Eli Lilly And Company Polypeptide compositions with improved stability
DK1274459T3 (da) 2000-04-19 2006-02-06 Genentech Inc Præparater med vedholdende frigivelse indeholdende væksthormon
WO2002036072A2 (en) * 2000-11-03 2002-05-10 Biomedicines, Inc. Method for short-term and long-term drug dosimetry
WO2003000282A1 (en) * 2001-06-21 2003-01-03 Genentech, Inc. Sustained release formulation
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
FR2868704B1 (fr) * 2004-04-07 2007-09-14 Ethypharm Sa Utilisation de lipides pour ameliorer la biodisponibilite de principes actifs proteiques en formulations injectables sous cutanees ou intra-musculaires
US7772182B2 (en) * 2004-08-05 2010-08-10 Alza Corporation Stable suspension formulations of erythropoietin receptor agonists
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
US8008453B2 (en) 2005-08-12 2011-08-30 Amgen Inc. Modified Fc molecules
KR101106510B1 (ko) 2006-05-30 2012-01-20 인타르시아 세라퓨틱스 인코포레이티드 투피스, 내부채널 삼투압 전달 시스템 유동 조절기
DK2049081T3 (da) 2006-08-09 2013-02-25 Intarcia Therapeutics Inc Osmotiske leveringssystemer og stempelarrangementer
CA2667678A1 (en) 2006-10-25 2008-07-24 Amgen Inc. Toxin peptide therapeutic agents
KR101434706B1 (ko) * 2007-02-16 2014-08-26 아스카 세이야쿠 가부시키가이샤 미립자 유성 현탁액을 포함하는 의약 조성물
US20080227805A1 (en) 2007-02-28 2008-09-18 Abbott Laboratories Sustained release parenteral formulations of buprenorphine
ES2402172T3 (es) 2007-04-23 2013-04-29 Intarcia Therapeutics, Inc Formulación en suspensión de péptidos insulinotrópicos y usos de los mismos
EP2162540A2 (en) 2007-05-22 2010-03-17 Amgen Inc. Compositions and methods for producing bioactive fusion proteins
EP2240155B1 (en) 2008-02-13 2012-06-06 Intarcia Therapeutics, Inc Devices, formulations, and methods for delivery of multiple beneficial agents
CN107638562B (zh) 2009-09-28 2022-12-02 精达制药公司 基本稳态药物递送的快速建立和/或终止
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
US9340590B2 (en) 2011-03-16 2016-05-17 Amgen Inc. Potent and selective inhibitors of NaV1.3 and NaV1.7
WO2014099984A1 (en) 2012-12-20 2014-06-26 Amgen Inc. Apj receptor agonists and uses thereof
WO2014165277A2 (en) 2013-03-12 2014-10-09 Amgen Inc. POTENT AND SELECTIVE INHIBITORS OF Nav1.7
CA2951391C (en) 2014-06-10 2021-11-02 Amgen Inc. Apelin polypeptides
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
US10925639B2 (en) 2015-06-03 2021-02-23 Intarcia Therapeutics, Inc. Implant placement and removal systems
BR112018073511A2 (pt) 2016-05-16 2019-03-26 Intarcia Therapeutics, Inc. polipeptídeos seletivos do receptor de glucagon e métodos de uso dos mesmos
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
MX2019008006A (es) 2017-01-03 2019-08-29 Intarcia Therapeutics Inc Metodos que comprenden la administracion continua de un agonista del receptor de glp-1 y la co-administracion de un farmaco.
US11318190B2 (en) 2017-05-05 2022-05-03 United States Government As Represented By The Department Of Veterans Affairs Methods and compositions for treating liver disease

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61500439A (ja) * 1983-11-21 1986-03-13 リ−ジエンツ オヴ ザ ユニヴア−シテイ− オヴ ミネソタ 慢性的非経口ホルモン投与用緩衝化ポリオ−ル−ホルモン混合物
US5411951A (en) * 1984-10-04 1995-05-02 Monsanto Company Prolonged release of biologically active somatotropin
EP0374120A3 (en) * 1988-12-13 1991-07-31 Monsanto Company Comosition for controlled release of polypeptides
US5114929A (en) * 1989-03-21 1992-05-19 Beecham Group P.L.C. Pharmaceutical formulation
US6004549A (en) * 1994-12-14 1999-12-21 Schering Corporation Crystalline protein controlled release compositions

Also Published As

Publication number Publication date
ES2204187T3 (es) 2004-04-16
JP2002533378A (ja) 2002-10-08
CN1158068C (zh) 2004-07-21
KR100491815B1 (ko) 2005-05-27
HUP0104756A3 (en) 2006-04-28
HUP0104756A2 (hu) 2002-04-29
IL143706A (en) 2008-04-13
ATE251448T1 (de) 2003-10-15
EP1140018A1 (en) 2001-10-10
CN1335765A (zh) 2002-02-13
DE69911993D1 (de) 2003-11-13
KR20010099864A (ko) 2001-11-09
PT1140018E (pt) 2004-02-27
AU2483800A (en) 2000-07-31
CA2355618C (en) 2007-03-13
EP1140018B1 (en) 2003-10-08
TWI221777B (en) 2004-10-11
DE69911993T2 (de) 2004-05-19
AU769610B2 (en) 2004-01-29
SI1140018T1 (en) 2003-12-31
WO2000038652A1 (en) 2000-07-06
CA2355618A1 (en) 2000-07-06
DK1140018T3 (da) 2004-02-02

Similar Documents

Publication Publication Date Title
IL143706A0 (en) Polyol/oil suspensions for the sustained release of proteins
HK1036969A1 (en) Compounds and compositions for delivering active agents
ATE309007T1 (de) Transplantate für die wiederherstellung von osteochondralen schäden
NZ527157A (en) Compositions for delivering bisphosphonates
EP1015008A4 (en) COMPOUNDS AND COMPOSITIONS FOR THE ADMINISTRATION OF ACTIVE SUBSTANCES
AU2845599A (en) Pharmaceutical compositions and their use
HK1036970A1 (en) Compounds and compositions for delivering active agents.
IL133397A0 (en) Pharmaceutical compositions for oral administration, comprising an active substance and a cyclodextrin
MXPA01008611A (es) Compuestos y composiciones para suministrar agentes activos.
HK1028548A1 (en) Formulations for hydrophobic pharmaceutical agents
IL153297A0 (en) Compounds and compositions for delivering active agents
AU2274201A (en) Compounds and compositions for delivering active agents
CA2315767A1 (en) Autoclavable pharmaceutical compositions containing a chelating agent
MXPA04004567A (es) Compuestos y composiciones de fenoxi amina para adminstrar agentes activos.
GB2364641A (en) Stabilized oral pharmaceutical composition containing iodide and iodate and method
HK1022265A1 (en) Biodegradable microparticles for the sustained delivery of therapeutic drugs
WO2002100338A3 (en) Compound and composition for delivering active agents
EP1153611A3 (en) Pharmaceutical composition for the treatment of fibrosis
ECSP941154A (es) Procedimiento para preparar una composicion farmaceutica a base de ciclosporina
MX9701865A (es) Compuestos de dimetil-(3-aril-but-3-enil)-amino como ingredientes activos farmaceuticos.
EP1676832A3 (en) Compounds and compositions for delivering active agents
UA29770A (uk) Спосіб пригнічення репродукції вірусу імунодефіциту людини

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed